| Size | Price | Stock | Qty |
|---|---|---|---|
| 1g |
|
||
| 2g |
|
| Targets |
Fluoroquinolonic acid targets bacterial DNA gyrase and topoisomerase IV, essential enzymes involved in DNA replication, transcription, and repair. It binds to the enzyme-DNA complex, stabilizing DNA strand breaks created by DNA gyrase and topoisomerase IV. This action directly inhibits DNA synthesis in bacteria. The compound's cyclopropyl group, fluorine atom, and carboxylic acid functional group on the quinoline core are essential for its antibacterial activity.
|
|---|---|
| ln Vitro |
In vitro, Fluoroquinolonic acid has broad-spectrum activity against Gram-positive and Gram-negative bacteria. It acts as a direct inhibitor of DNA synthesis by binding to the enzyme-DNA complex and stabilizing DNA strand breaks. Its mechanism of action affects the biochemical pathway of DNA synthesis in bacteria. Specific MIC values are not detailed in the available literature. The compound is structurally related to ciprofloxacin and is used as a reference standard for impurity analysis.
|
| ln Vivo |
Specific in vivo data for Fluoroquinolonic acid are limited. As a bacteriostatic antibiotic, the compound would have potential for in vivo efficacy studies in bacterial infection models. However, specific published in vivo protocols for this compound are not detailed. The compound is primarily used as a research standard and impurity reference for ciprofloxacin rather than as a therapeutic agent. Further studies are needed to evaluate its in vivo efficacy.
|
| Enzyme Assay |
The antibacterial activity is assessed using standard broth microdilution or agar diffusion methods following CLSI guidelines. Bacterial strains (Gram-positive and Gram-negative) are cultured in appropriate media and treated with serial dilutions of Fluoroquinolonic acid. The MIC is defined as the lowest concentration that inhibits visible growth. DNA gyrase and topoisomerase IV inhibition are assessed using enzyme activity assays with purified enzymes and supercoiled DNA substrates.
|
| Cell Assay |
For cellular studies, bacterial cultures are grown in appropriate broth media. Fluoroquinolonic acid is added at various concentrations, and bacterial growth is monitored by measuring optical density at 600 nm or by colony counting on agar plates. The compound is typically dissolved in DMSO or 0.1N NaOH and diluted in culture media. The compound has a molecular formula of C₁₃H₉ClFNO₃ and a molecular weight of 281.67 g/mol. It is soluble in DMSO at 25 mg/mL.
|
| Animal Protocol |
In vivo studies for Fluoroquinolonic acid would be conducted in appropriate infection models. Mouse models of bacterial infection would be used, with the compound administered via oral gavage or intraperitoneal injection. Bacterial burden in tissues would be measured, and survival rates would be monitored. However, specific published protocols for this compound are not available. The compound is primarily used as a research standard rather than a therapeutic agent.
|
| ADME/Pharmacokinetics |
Specific pharmacokinetic data for Fluoroquinolonic acid are not extensively reported. The compound has a molecular weight of 281.67 g/mol and is soluble in DMSO at 25 mg/mL. As a fluoroquinolone derivative, it would be expected to have similar PK properties to other fluoroquinolones, including good oral bioavailability, tissue distribution, and renal elimination. The compound should be stored as a powder at -20°C for up to 3 years or at 4°C for up to 2 years.
|
| Toxicity/Toxicokinetics |
Specific toxicological data for Fluoroquinolonic acid are not reported. As a fluoroquinolone derivative, potential toxicities would be similar to other drugs in this class, including gastrointestinal effects, central nervous system effects, and tendon toxicity. The compound is primarily used as a research standard and impurity reference, and comprehensive toxicology studies for this specific compound have not been reported. Standard safety precautions should be taken when handling.
|
| Additional Infomation |
Fluoroquinolonic acid is a bacteriostatic antibiotic with broad-spectrum antibacterial activity. It inhibits bacterial DNA gyrase and topoisomerase IV. Molecular formula: C₁₃H₉ClFNO₃, MW: 281.67. Also known as Ciprofloxacin Impurity A. For research use only as a reference standard.
|
| Molecular Formula |
C13H9CLFNO3
|
|---|---|
| Molecular Weight |
281.67
|
| Exact Mass |
281.025
|
| CAS # |
86393-33-1
|
| PubChem CID |
483180
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.7±0.1 g/cm3
|
| Boiling Point |
467.3±45.0 °C at 760 mmHg
|
| Melting Point |
242-245 °C(lit.)
|
| Flash Point |
236.4±28.7 °C
|
| Vapour Pressure |
0.0±1.2 mmHg at 25°C
|
| Index of Refraction |
1.683
|
| LogP |
2.16
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
19
|
| Complexity |
463
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C(C1C(=O)C2C(=CC(=C(C=2)F)Cl)N(C2CC2)C=1)O
|
| InChi Key |
ISPVACVJFUIDPD-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C13H9ClFNO3/c14-9-4-11-7(3-10(9)15)12(17)8(13(18)19)5-16(11)6-1-2-6/h3-6H,1-2H2,(H,18,19)
|
| Chemical Name |
7-chloro-1-cyclopropyl-6-fluoro-4-oxoquinoline-3-carboxylic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~16.67 mg/mL (~59.18 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.67 mg/mL (5.93 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 16.7 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.5503 mL | 17.7513 mL | 35.5025 mL | |
| 5 mM | 0.7101 mL | 3.5503 mL | 7.1005 mL | |
| 10 mM | 0.3550 mL | 1.7751 mL | 3.5503 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
